علاج داء كرون النشط خفيف إلى معتدل الشدة مع إصابة المنطقة اللفائفية الأعورية

References

DOI: 10.14309/ajg.0000000000003465

We recommend controlled ileal release budesonide at a dose of 9 mg daily for induction of symptomatic remission in patients with mildly to moderately active ileocecal CD (strong recommendation, moderate level of evidence).

For adult patients with mild CD and low risk of progression, diet-based strategies along with careful monitoring for inadequate symptom relief, worsening inflammation, or disease progression may be considered.

We recommend against the use of oral mesalamine for induction or maintenance in patients with mildly to moderately active CD (strong recommendation, moderate level of evidence).

In general, clinical evidence of improvement should be evident within 2–4 weeks, and the maximal improvement should occur by 12–16 weeks.